Predictive potential of IL-18 -607 and osteopontin -442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population

Viral Immunology

Volumn 27, Issue 8, 2014, Pages 404-411

  Imran, Muhammad ^a   Manzoor, Sobia ^a   Parvaiz, Fahed ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; INTERLEUKIN 18; N ACETYLGALACTOSAMINYLTRANSFERASE; N ACETYLGALACTOSAMINYLTRANSFERASE 8; OSTEOPONTIN; RIBAVIRIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ALPHA INTERFERON; INTERLEUKIN 18 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAKISTANI; POLYMERASE CHAIN REACTION; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE; ADOLESCENT; GENETICS; GENOTYPING TECHNIQUE; HEPATITIS C, CHRONIC; MIDDLE AGED; PAKISTAN; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-18; MALE; MIDDLE AGED; OSTEOPONTIN; PAKISTAN; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907504496     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2014.0044     Document Type: Article

References (55)

1. Afzal MS, Tahir S, Salman A, et al. Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries 2011;5:473-479.
2. Ahmad B, Ali S, Ali I, et al. Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK). Virol J 2012 9:18.
3. Asakawa M, Kono H, Amemiya H, et al. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer 2006;118:564-570.
4. Aziz H, Gil ML, Waheed Y, et al. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Infect Genet Evol 2011;11:640-645.
5. Bellanti F, Vendemiale G, Altomare E, and Serviddio G. The impact of Interferon Lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Devel Immunol 2012, Article ID 849373.
6. Bouzgarrou N, Hassen E, Farhat K, et al. Combined analysis of interferon-c and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 2009;70:230-236.
7. Cao W, and Liu Y-J. Opn: key regulator of pDC interferon production. Nat Immunol 2006;7:441-443.
8. Cheng K, and Mahato RI. Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst 2007;24:93-146.
9. Chirathaworn C, Rianthavorn P, Wuttirattanakowit N, and Poovorawan Y. Serum IL-18 and IL-18BP levels in patients with Chikungunya virus infection. Viral Immunol 2010;23: 113-117.
10. Darawi MN, Ai-Vyrn C, Ramasamy K, et al. Allele-specific polymerase chain reaction for the detection of Alzheimer's disease-related single nucleotide polymorphisms. BMC Med Genet 2013;14:27.
11. Diepolder H, Zachoval R, Hoffmann R, et al. Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-1007.
12. Eurich D, Bahra M, Boas-Knoop S, et al. Transforming growth factor b1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus-induced liver disease. Liver Transpl 2011;17:279-288.
13. Farid S, Rashid L, and Swelam S. The role of interleukin-18 promoter polymorphisms (-607 C/A and 137 G/C) in determining HCV clearance or persistence. Egypt J Hosp Med 2013;50:141-149.
14. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
15. Gewaltig J, Mangasser-Stephan K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCVinduced liver fibrosis. Clin Chim Acta 2002;316:83-94.
16. Giachelli CM, and Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000;19:615-622.
17. Gracie J, Koyama N, Murdoch J, et al. Disease association of two distinct interleukin-18 promoter polymorphisms in Caucasian rheumatoid arthritis patients. Genes Immun 2005;6:211-216.
18. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type b1. Hum Mol Genet 1999;8:93-97.
19. Hejr S, KarimiMH, Yaghobi R, et al. Association of IL-17, IL-21, and IL-23R gene polymorphisms with HBV infection in kidney transplant patients. Viral Immunol 2013;26:201-206.
20. Huang W, Zhu G, Huang M, et al. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta 2010;411:675-678.
21. Ide A, Kawasaki E, Abiru N, et al. Association between IL-18 gene promoter polymorphisms and CTLA-4 gene 49A/G polymorphism in Japanese patients with type 1 diabetes. J Autoimmun 2004;22:73-78.
22. Imran M, Waheed Y, Manzoor S, et al. Interaction of hepatitis C virus proteins with pattern recognition receptors. Virol J 2012;9:126.
23. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-Alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-639.
24. Kimura K, Kakimi K, Wieland S, et al. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002;76:10702-10707.
25. Kimura T, Saito T, Yoshimura M, et al. Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis 2006;193:1371-1374.
26. Kretowski A, Mironczuk K, Karpinska A, et al. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes 2002;51:3347-3349.
27. Kruse S, Kuehr J, Moseler M, et al. Polymorphisms in the IL 18 gene are associated with specific sensitization to common allergens and allergic rhinitis. J Allergy Clin Immunol 2003;111:117-122.
28. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
29. Lee SH, Seo GS, Park YN, et al. Effects and regulation of osteopontin in rat hepatic stellate cells. Biochem Pharmacol 2004;68:2367-2378.
30. Manohar K, Suneetha P, Pati NT, et al. Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients. Hepatol Int 2009;3:371-377.
31. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med 1998; 339:1485-1492.
32. Mochida S, Hashimoto M, Matsui A, et al. Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 2004;313:1079-1085.
33. Naito M, Matsui A, Inao M, et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005;40:381-388.
34. Nakano R, Maekawa T, Abe H, et al. Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C. J Gen Virol 2013;94:81-89.
35. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-A therapy. Science 1998;282:103-107.
36. Novak N, Kruse S, Potreck J, et al. Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. J Allergy Clin Immunol 2005;115:828-833.
37. Okumoto K, Hattori E, Tamura K, et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004;24:21-28.
38. Österreicher CH, Datz C, Stickel F, et al. TGF-b1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 2005;31:142-148.
39. Rauch A, Kutalik Z, Descombes P, et al. 2010 Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-1345.
40. Sato M, Suzuki S, and Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003;28:105-112.
41. Segat L, Bevilacqua D, Boniotto M, et al. IL-18 gene promoter polymorphism is involved in HIV-1 infection in a Brazilian pediatric population. Immunogenetics 2006;58: 471-473.
42. Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol 2014;30:217-222.
43. Sivalingam S, Yoon K, Koh D, and Fong K. Single-nucleotide polymorphisms of the interleukin-18 gene promoter region in rheumatoid arthritis patients: protective effect of AA genotype. Tissue Antigens 2003;62:498-504.
44. Sodek J, Ganss B, and McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000;11:279-303.
45. Sun J, Xu H-M, Zhou H-J, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:1-7.
46. Taniguchi H, Kato N, Otsuka M, et al. Hepatitis C virus core protein upregulates transforming growth factor-b1 transcription. J Med Virol 2004;72:52-59.
47. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Nat Acad Sci 2002;99: 15661-15668.
48. Vecchiet J, Falasca K, Cacciatore P, et al. Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-Alcoholic fatty liver disease. Ann Clin Lab Sci 2005;35:415-422.
49. Xie H, Song J, Du R, et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Digest Liver Dis 2007;39:167-172.
50. Yang Y, Qiao J, and Li M-z. Association of polymorphisms of interleukin-18 gene promoter region with polycystic ovary syndrome in chinese population. Reprod Biol Endocrinol 2010;8:125.
51. Yao E, and Tavis JE. A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J 2005;2:1-9.
52. Yoneda S, Umemura T, Katsuyama Y, et al. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011;203:1087-1095.
53. Zecchina G, Novick D, Rubinstein M, et al. Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. J Hematother Stem Cell Res 2001;10:769-776.
54. Zeuzem S, Herrmann E, Lee J-H, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon a2a. Gastroenterology 2001;120:1438-1447.
55. Zhao L, Li T, Wang Y, et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 2008;62:1056-1062.